| --- | --- | |-----------------------------------------------------------------|-------| | | | | An Open-label, Phase 1/2 Trial of Gene Therapy | | | 4D-310 in Adult Males with Fabry Disease Jerry Vockley, MD, PhD | | | University of Pittsburgh, Pittsburgh, Pennsylvania, USA | | 4D-310 Product Design: Unique Dual Mechanism-of-Action INVENTED FOR LOW DOSE IV DELIVERY TO TARGET ORGANS INCLUDING HEART & HIGH SERUM AGA Patient with Fabry Disease Biodistribution to affected organs Blood vessel dysfunction Cardi ...